Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

Thumbnail

Fan dies after heart attack at World Cup

A Brazilian soccer fan died after experiencing an MI at the close of a dramatic World Cup match between Brazil and Chile that allowed Brazil to advance to the quarter finals.

Left radial PCI reduces operators’ radiation exposure by half

Radiation exposure to the operator was nearly half when performing PCI by a left radial approach rather than right, according to a study published online June 18 in the Journal of the American College of Cardiology: Cardiovascular Interventions. 

Angiography as good as FFR & IVUS for post-PCI long-term survival

While fractional flow reserve (FFR) and intravascular ultrasound (IVUS) may reduce the need for repeat revascularization, they apparently don’t make a dent in long-term mortality compared with angiography-guided PCI. But FFR may help reduce stent use, according to results published online June 23 in JAMA Internal Medicine.

Thumbnail

Preoperative beta-blocker use may not help with CABG

The latest study to examine the preoperative use of beta-blockers in CABG found no mortality benefit combined with an uptick in postoperative atrial fibrillation. Still, it probably is not time to take an eraser to related quality metrics or guidelines. 

A break for CABG? Readmissions measure uses clinical data

With penalties for higher-than-expected 30-day readmissions for CABG on the horizon, concerns about how hospitals will be measured have been growing. A method that linked clinical data to administrative data may provide an answer.

Global leader projects introduction of IN.PACT Admiral Drug-coated Balloon to U.S. market in early FY16

Moving toward U.S. market introduction of its novel medical device to treat peripheral artery disease, Medtronic, Inc. (NYSE: MDT) today announced that it recently submitted the final module of its pre-market approval (PMA) application for the IN.PACT Admiral drug-coated balloon to the U.S. Food and Drug Administration (FDA). The application includes data that demonstrates superior clinical outcomes compared with conventional angioplasty, with the lowest rates of repeat procedures (target lesion revascularization) and the highest rate of uninterrupted blood flow (primary patency) at 12 months ever reported for the interventional treatment of peripheral artery disease.

Thumbnail

Increasing radial PCI use even slightly may lower bleeding rates

Hospitals that readily embraced transradial PCI over a three-year period were more likely to see reduced bleeding rates, an analysis of CathPCI data showed. But even facilities that had modest increases in radial PCI use achieved lower access site and overall bleeding rates.

Thumbnail

Off-pump CABG shows short- but not long-term kidney benefits

Patients who underwent off-pump CABG surgery were less likely than on-pump patients to experience postoperative acute kidney injury, based on an analysis of CORONARY data published in the June 4 issue of JAMA. But kidney function remained similar between the groups at one year.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.